Dec. 8, 2011
/PRNewswire/ -- Transcept Pharmaceuticals, Inc. (Nasdaq: TSPT), a specialty pharmaceutical company focused on the development and commercialization of proprietary products that address important therapeutic needs in the field of neuroscience, today announced that Transcept management is scheduled to present at the Oppenheimer & Co. Healthcare Conference in
December 13, 2011
10:15 a.m. ET
A live audio webcast and replay of this presentation may be accessed at
and on the Transcept Investor webpage at
About Transcept Pharmaceuticals
Transcept Pharmaceuticals, Inc. is a specialty pharmaceutical company focused on the development and commercialization of proprietary products that address important therapeutic needs in the field of neuroscience.
Intermezzo® (zolpidem tartrate) sublingual tablet C-IV is the first FDA approved Transcept product and is indicated for use as needed for the treatment of insomnia when a middle-of-the-night awakening is followed by difficulty returning to sleep. Intermezzo is not indicated for the treatment of middle-of-the-night insomnia when the patient has fewer than 4 hours of bedtime remaining before the planned time of waking. Patients should be cautioned about possible combined effects with CNS-depressant drugs. Intermezzo should not be taken with alcohol. The most commonly reported adverse reactions in clinical trials with Intermezzo were headache, nausea and fatigue. Transcept and
have entered into a collaboration agreement for the development and commercialization of Intermezzo in
the United States
Transcept is currently conducting a Phase 2 study of an investigational product, TO-2061, in patients with obsessive-compulsive disorder.
For further information about Transcept, please visit
Transcept Pharmaceuticals, Inc.
Director, Corporate Communications(510) 215-3567
SOURCE Transcept Pharmaceuticals, Inc.